Australia's most trusted
source of pharma news
Monday, 07 October 2024
Posted 27 September 2024 AM
Pfizer has announced it is voluntarily withdrawing its sickle cell disease (SCD) treatment Oxbryta from all markets.
The move is based on "the totality of clinical data", which suggest an "imbalance in vaso-occlusive crises and fatal events", according to the pharma. This indicates that the overall benefit of Oxbryta can no longer be considered to outweigh the risk in the approved sickle cell patient population.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.